Article
Once-Daily Formulation of Belviq Under FDA Review
Author(s):
The FDA has accepted Eisai Co Ltd's new drug application for a once-daily formulation of its anti-obesity treatment lorcaserin hydrochloride.
The FDA has accepted Eisai Co Ltd’s new drug application for a once-daily formulation of its anti-obesity treatment lorcaserin hydrochloride (Belviq).
Belviq has been available in the United States as a twice-daily formulation since 2013.
The serotonin 2C receptor agonist was approved by the FDA in 2012 as an adjunct to a reduced-calorie diet and increased physical activity for overweight patients.
Adverse effects associated with Belviq include headache, dizziness, fatigue, nausea, and dry mouth.
The medication is also currently being investigated in a cardiovascular outcomes trial, which is looking at Belviq's potential to cause major adverse cardiovascular events. Results from this study will become available in 2018.
A phase 2 clinical trial demonstrated that Belviq could be an effective smoking cessation aid.
Around 170 million people in the United States are obese or overweight.
FDA Approves Dupilumab, Marking First Targeted Therapy in a Decade for Chronic Spontaneous Urticaria
